Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications. Continue reading.
miércoles, 7 de marzo de 2018
FDA approves new HIV treatment for patients who have limited treatment options
Press Announcements > FDA approves new HIV treatment for patients who have limited treatment options
![](https://blogger.googleusercontent.com/img/proxy/AVvXsEhmNymzf199_DVLtHiWvEg46OWOWnk_RaCwPfFFvl22zQLuukx9iwtkDpSn_u5AEyX41YlAKQqzJHeAYemhXe87qldBtEyCSqzNcgS-twkU_9cxw0avlOf49Lq8HzmTAB6ojGQlJFg5VNicAl4NX5VXxZs4NZvAMJLbo6eBC-2KH1_aIm-cpz-cRxv7gnNrNuiaDJGPANKhgPEe-pxAy2l892CK2JLRDx3oux5PiDsId1DYM219ifdC65Eq4N_gN2ZTXm2lPcdb0gWYoAg4fzk0Fj0154DmcA=s0-d-e1-ft)
Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications. Continue reading.
Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications. Continue reading.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario